A magnetic resonance probe may include a plurality of center conductors, at least some center conductors including a conductive core and an insulator disposed at least partially about the core along at least a portion of the core, a first dielectric layer disposed at least partially about the plurality of center conductors in a proximal portion of the probe, an outer conductive layer at least partially disposed about the first dielectric layer, and a plurality of electrodes, at least one electrode being coupled to one of the center conductors and disposed at least partly on a probe surface.
|
0. 34. A magnetic resonance (MR) probe, comprising:
a plurality of center conductors residing closely spaced together in a medial portion of an MR probe body, each conductor having a conductive core and an insulator disposed over the conductive core;
a first dielectric layer residing over the plurality of center conductors;
a conductive shield layer residing over the first dielectric layer; and
a plurality of electrodes, at least one attached to a respective one of the plurality of conductors,
wherein the plurality of center conductors define a first pole and the conductive shield defines a second pole of a loopless magnetic resonance dipole antenna.
1. A magnetic resonance probe, comprising:
a plurality of center conductors, at least some center conductors;
including a conductive core and an insulator disposed at least partially about the core along at least a portion of the core; and
forming a first pole of a magnetic resonance dipole antenna;
a first dielectric layer disposed at least partially about the plurality of center conductors in a proximal portion of the probe;
an outer conductive layer at least partially disposed about the first dielectric layer and forming a second pole of the magnetic resonance dipole antenna; and
a plurality of electrodes, at least one electrode being coupled to one of the center conductors and disposed at least partly on a probe surface.
32. A combined magnetic resonance imaging and electrophysiology probe, comprising:
a plurality of center conductors, at least some center conductors including a conductive core and an insulator disposed at least partially about the core along at least a portion of the core, the insulator having a thickness equal to or less than about 100 microns;
a first dielectric layer disposed at least partially about the plurality of center conductors in a proximal portion of the probe;
an outer conductive layer at least partially disposed about the first dielectric layer;
a second dielectric layer disposed at least partially about the outer conductive layer; and
a plurality of electrodes, at least one electrode coupled to one of the center conductors and disposed at least partly on the probe surface.
33. A system for magnetic resonance imaging, comprising:
a magnetic resonance probe, including:
a plurality of center conductors, at least some center conductors:
including a conductive core and an insulator disposed at least partially about the core along at least a portion of the core; and
forming a first pole of a magnetic resonance dipole antenna;
a first dielectric layer disposed at least partially about the plurality of center conductors in a proximal portion of the probe;
an outer conductive layer disposed at least partially about the first dielectric layer and forming a second pole of the magnetic resonance dipole antenna; and
a plurality of electrodes, at least one electrode coupled to one of the center conductors and disposed at least partly on the probe surface; and
a interface electrically coupled to the probe, the interface including:
a signal splitter that directs a signal received from the probe to a magnetic resonance pathway and an electrophysiology pathway;
a high-pass filter disposed in the magnetic resonance pathway;
a low-pass filter disposed in the electrophysiology pathway;
a connector disposed in the magnetic resonance pathway for connecting to a magnetic resonance scanner; and
a connector disposed in the electrophysiology pathway for connecting to at least one of a tissue stimulator, a electrophysiological recording system, and an ablation energy source.
2. The probe of
3. The probe of
4. The probe of
5. The probe of
6. The probe of
7. The probe of
8. The probe of
9. The probe of
a ribbon disposed in a distal portion of the probe; and
a pull wire coupled to the ribbon.
12. The probe of
13. The probe of
14. The probe of
15. The probe of
16. The probe of
a signal splitter that directs a signal received from the probe to a magnetic resonance pathway and an electrophysiology pathway;
a high-pass filter disposed in the magnetic resonance pathway;
a low-pass filter disposed in the electrophysiology pathway;
a connector disposed in the magnetic resonance pathway for connecting to a magnetic resonance scanner; and
a connector disposed in the electrophysiology pathway for connecting to at least one of a tissue stimulator, a biopotential recording system, and an ablation energy source.
19. The probe of
an outer conductor contact coupled to the outer conductive layer;
extended sections of at least some center conductors extending proximally beyond the outer conductor contact, at least one extended section having a center conductor contact coupled to one center conductor; and
an insulated area interposed between the outer conductor contact and the at least one center conductor contact.
21. The probe of
22. The probe of
23. The probe of
24. A method of performing a magnetic resonance-guided procedure, comprising:
placing a subject in a magnetic resonance scanner;
identifying a target site in the subject using data about the subject obtained from the scanner;
introducing into the patient subject, a magnetic resonance probe as defined by
advancing the probe to the target site; and
performing the procedure using the magnetic resonance probe.
25. The method of
26. The method of
27. The method of
28. The method of
29. The method of
30. The method of
31. The method of
0. 35. A probe according to claim 34, wherein the insulator has a thickness equal to or less than about 100 microns.
0. 36. A probe according to claim 34, wherein the closely spaced plurality of center conductors permit electrical coupling of magnetic resonance energy at a frequency above 10 MHz to thereby define a single electrical entity to define an antenna that receives MR signals.
0. 37. A probe according to claim 34, wherein the closely spaced plurality of center conductors inhibit coupling of low-frequency energy between the center conductors below 0.5 MHz.
0. 38. A probe according to claim 34, wherein the probe is devoid of reactive elements between center conductors proximate the electrodes.
0. 39. A probe according to claim 37, further comprising a decoupling circuit in communication with the center conductors and outer conductive layer whereby the antenna is decoupled from RF transmitted by the MRI system so that tissue adjacent the probe electrodes do not receive undue RF energy deposition at the MRI system operating frequency during the transmit operation of the MRI system.
0. 40. A probe according to claim 38, wherein the loopless antenna defines an MRI visualization length that extends from a portion of the shield and the conductors extending outwardly there from about a distal portion of the probe, such that the first pole has a length between about 3-15 cm.
0. 41. A probe according to claim 40, wherein the electrodes can detect EP signals independent of the transmit/receive operation of the MRI system.
0. 42. A probe according to claim 41, wherein tissue stimulation or ablation energy can be delivered through one or more of the electrodes independent of the transmit/receive operation of the MRI system.
0. 43. A probe according to claim 34, wherein some of the center conductors contact each other.
0. 44. A probe according to claim 43, wherein the insulator is a thin insulator.
0. 45. A probe according to claim 34, wherein the probe body has a flexible distal end whereby the probe body is deflectable.
0. 46. A probe according to claim 34, wherein the plurality of conductors with an outer insulator are at least four insulated wires that connect to a respective one of at least four spaced apart electrodes.
0. 47. A probe according to claim 34, further comprising an interface circuit in communication with the center conductors, wherein the interface circuit has a signal splitter defining an MR pathway with a high pass filter and an EP pathway with a low pass filter, the signal splitter in communication with the plurality of conductors to define a simultaneous EP recording and MR imaging catheter.
0. 48. A probe according to claim 34, wherein at least one of the center conductors defines a combination pull wire and center conductor.
0. 49. A probe according to claim 34, wherein the probe electrodes are sized and configured for deep brain stimulation and recording, and wherein the plurality of center conductors cooperate with the probe conductive shield to function as a magnetic resonance receive antenna.
0. 50. A probe according to claim 34, wherein the probe has a deflectable flexible distal tip portion holding at least some of the electrodes, wherein the probe is a cardiac EP probe with the electrodes configured to ablate cardiac tissue.
|
This application claims the benefit of U.S. provisional application Ser. No. 60/383,828, filed May 29, 2002, which is hereby incorporated herein in its entirety by this reference.
Leads (catheters) for a wide variety of medical procedures, such as Deep Brain Stimulation (DBS) and cardiac interventions, are typically placed into the body of a subject under stereotactic guidance, fluoroscopy, or other methods. Stereotactic guidance is a static method based on high resolution images taken prior to the procedure and does not take into account displacement of the brain caused by the loss of cerebral spinal fluid (CSF), blood or simple brain tissue displacement by the surgical tool. It is therefore often necessary to perform a real time physiological localization of the target area to augment and verify the previously obtained stereotactic data by observing the patients response to stimulation through the DBS electrodes or by recording and displaying (visual or audible) the action potentials of individual neurons along the path way to the target zone using microelectrodes. These additional steps are time consuming; resulting in procedures between 6-8 hours with a failure rate still remaining between 20-30%.
Cardiac procedures are mainly performed using X-ray fluoroscopy. Because X-ray shadows are the superposition of contributions from many structures, and since the discrimination of different soft tissues is not great, it is often very difficult to determine exactly where the catheter is within the heart. In addition, the borders of the heart are generally not accurately defined, so it is generally not possible to know whether the catheter has penetrated the wall of the heart. Furthermore, lesions are invisible under x-ray fluoroscopy. Thus, it is very difficult to discern whether tissue has been adequately ablated.
The systems and methods disclosed herein may simplify the manufacturing process for magnetic resonance probes, increase patient safety, reduce if not eliminate tissue heating, and facilitate the performance of multiple functions during MRI interventional procedures such as Deep Brain Stimulation, Electrophysiological Mapping, and/or RF Ablation.
In an embodiment, a magnetic resonance probe may include a plurality of center conductors, at least some center conductors including a conductive core and an insulator disposed at least partially about the core along at least a portion of the core. A first dielectric layer may be disposed at least partially about the plurality of center conductors in a proximal portion of the probe. An outer conductive layer may be at least partially disposed about the first dielectric layer. A plurality of electrodes may be included, at least one electrode being coupled to one of the center conductors and disposed at least partly on a probe surface.
In an embodiment, a probe may include a second dielectric layer at least partially disposed about the outer conductor. In an embodiment, the plurality of center conductors may be magnetic resonance-compatible. In an embodiment, at least one insulator may have a thickness up to about 100 microns. In an embodiment, at least some center conductors may form a first pole of a dipole antenna, and the outer conductive layer may form a second pole of the dipole antenna. In an embodiment, a probe can include a plurality of radially expandable arms. In an embodiment, at least one electrode may be at least partly disposed on an arm.
In an embodiment, an interface circuit may be electrically coupled to the probe, the interface circuit including a signal splitter that directs a signal received from the probe to a magnetic resonance pathway and an electrophysiology pathway, a high-pass filter disposed in the magnetic resonance pathway, a low-pass filter disposed in the electrophysiology pathway, a connector disposed in the magnetic resonance pathway for connecting to a magnetic resonance scanner, and a connector disposed in the electrophysiology pathway for connecting to at least one of a tissue stimulator, a biopotential recording system, and an ablation energy source.
Embodiments of the disclosed systems and methods will be apparent from the following more particular description of exemplary embodiments as illustrated in the accompanying drawings, in which some reference characters refer to the same parts throughout the various views. The drawings are not necessarily to scale, nor are individual elements necessarily in relative proportion to other elements, emphasis instead being placed upon illustrating principles of the disclosed systems and methods.
The disclosed systems and methods relate to the guidance and visualization of diagnostic and therapeutic procedures performed under Magnetic Resonance Imaging (MRI). Such procedures in general benefit from the excellent soft tissue contrast obtainable with MRI. Examples of such applications are Deep Brain Stimulation (DBS) for the treatment of movement disorders (Parkinson's disease, Essential tremor, etc.) and other neurological disorders benefiting from electrical stimulations of section of the brain, as well as the diagnosis and treatment of cardiac arrhythmias including but not limited to atrial fibrillation and ventricular tachycardia.
Real time Magnetic Resonance Imaging can overcome both the inaccuracies of stereotactic planning and the lack of soft tissue contrast as found in X-ray fluoroscopy. The use of Magnetic Resonance Imaging guided interventions can therefore result in shortened procedure times and increased success rates.
Some conditions that may benefit from MRI-guided DBS include Parkinson's disease, essential tremor, and multiple sclerosis. Parkinson's disease is a progressive neurological disorder in regions of the midbrain containing a cluster of neurons known as the “substantia nigra.” These neurons produce the chemical dopamine, a neurotransmitter (messenger) responsible for transmitting signals between the substantia nigra and several clusters of neurons that comprise the basal ganglia and is vital for normal movement. When dopamine levels drop below 80%, symptoms of Parkinson's disease begin to emerge causing nerve cells of the basal ganglia to fire out of control; resulting in tremor, muscle stiffness or rigidity, slowness of movement (bradykinesia) and loss of balance. Although medication masks some symptoms for a limited period, generally four to eight years in most patients, they begin causing dose-limiting side effects. Eventually the medications lose their effectiveness, leaving the patient unable to move, speak or swallow. Several preventive and restorative strategies such as neural cell transplantation, neural growth factors, gene therapy techniques and surgical therapies (including DBS), have shown promise in animal studies and human clinical trials. Important links to the cause (including genetic susceptibility and the role of toxic agents) are becoming established. Leading scientists describe Parkinson's as the neurological disorder most likely to produce a breakthrough therapy and/or cure within this decade. Parkinson's disease afflicts approximately 1 million Americans, nearly 40 percent of whom are under the age of 60. Roughly 60,000 cases of PD are diagnosed each year. It is estimated that Parkinson's disease costs society $25 billion or more annually.
Essential tremor (ET) is considered the most common neurological movement disorder affecting nearly 10 million people in the United States. ET is a chronic condition characterized by involuntary, rhythmic tremor of a body part, most typically the hands and arms, often the head and voice, but rarely the legs. ET is generally considered a slowly progressive disorder, although many individuals may have a mild form of ET throughout life that never requires treatment. The most common form of ET affects the arms and hands, usually bilaterally, and is most prominent with the arms held against gravity (postural tremor) or in action (kinetic tremor) such as when writing or drinking from a cup. Unlike patients with Parkinson's disease, patients with ET rarely exhibit a tremor when the arm is at rest. Pharmacological treatment for ET includes a class of drugs called Beta-adrenergic blocking agents (such as propranolol), benefiting about 50 to 60 percent of patients. Primidone (MYSOLINE) is commonly regarded as the most effective drug. Side effects of these drugs include: bradycardia (slow heart rate), hypotension (low blood pressure), dizziness, fatigue, depression, diarrhea, nausea and/or sexual dysfunction. Surgical treatment of ET has for years involved placing a lesion in certain cluster of cells called the thalamus. This procedure, called stereotaxic thalamotomy has been quite effective in substantially reducing tremor intensity, although there is a finite risk of stroke or other surgical complications and bilateral thalamotomies increase the risk of speech impairment (dysarthria). The recent development of high frequency stimulation of the thalamus (deep brain stimulation) has provided a safer and more effective surgical strategy for treating ET. This procedure involves the placement of an electrode in a region of the thalamus (Ventral Intermediate Nucleus or VIM).
Multiple sclerosis (MS) tends to begin in young adulthood and affects about 500,000 people in the United States. Worldwide, the incidence rate is approximately 0.01 % with Northern Europe and the northern US having the highest prevalence with more than 30 cases per 100,000 people. MS is a chronic, progressive, degenerative disorder that affects nerve fibers in the brain and spinal cord. A fatty substance (called myelin) surrounds and insulates nerve fibers and facilitates the conduction of nerve impulse transmissions. MS is characterized by intermittent damage to myelin (called demyelination) caused by the destruction of specialized cells (oligodendrocytes) that form the substance. Demyelination causes scarring and hardening (sclerosis, plague) of nerve fibers usually in the spinal cord, brain stem, and optic nerves, which slows nerve impulses and results in weakness, numbness, pain, and vision loss. MS can affect any part of the central nervous system. When it affects the cerebellum or the cerebellum's connections to other parts of the brain, severe tremor can result. Since the sub cortical gray matter also contains myelinated nerve fibers, plaques can also be found in the striatum, pallidum and thalamus. This may be the pathological basis for the other movement disorders seen in a small proportion of patients with MS. Because different nerves are affected at different times, MS symptoms often exacerbate (worsen), improve, and develop in different areas of the body. Early symptoms of the disorder may include vision changes (e.g., blurred vision, blind spots) and muscle weakness. MS can progress steadily or cause acute attacks (exacerbations) followed by partial or complete reduction in symptoms (remission). Most patients with the disease have a normal lifespan.
In a typical DBS procedure, a stereotactic frame, e.g. an Ieksell frame, is attached (bolted) to the patient prior to any portion of the surgical intervention. This is often done in a separate small operating room, either under sedation (Midazolam, Fentanyl, Propofol) and/or local anesthesia (Lidocaine). After the frame is attached, the patient is transferred to the table of the imaging system (CT or MR) and the patient's head is immobilized. A box containing fiduciary markers is fitted on to the frame. These markers will show up in subsequent images in precisely known locations, allowing an accurate mapping between the frame coordinates and brain structures. Based on these detailed images and coordinate mappings, the trajectory for the surgery using a planning software program.
Typical targets for the procedure include regions in the Thalamus, the Globus Pallidum Internus (Gpi) and the Subthalamic Nucleus (SNT). The target selection strongly depends on the disease and symptoms treated. DBS in the GPi seems to be very effective for drug-induced dyskinesia and helps control tremor and bradykinesia. DBS in the SNT seem to be most effective as measured by ability of patients to reduce their medications, however, there is a potential for increasing dyskinesia. The Thalamus is not necessarily a good target for patients with Parkinson's disease but has been found to improve conditions for patients with Essential Tremor and movement disorder caused by Multiple Sclerosis.
Once the target has been effectively localized and noted to be in a safe location, effort must be placed on a safe entry and trajectory to the target. MRI surface images of the cerebral cortex in combination with the DBS planning scans can be useful to avoid injuries to cerebral arteries or veins at the initial drill holes and due to passage of the DBS electrode, resulting in a catastrophic hemorrhage. With the stereotactic software system, trajectory slices are possible so that every stage of the trajectory can be visualized in terms of its potential harm as an electrode is passed toward the target. Fine adjustments to the entry point can be made to avoid these critical structures or avoid passage through the ventricular system in the patient with large ventricles.
Entry point coordinates are not directly utilized during operative planning but are used by the computer system in creating the trajectory itself. An estimate of accuracy can then be obtained and is usually accurate within several hundred microns and always less than 0.5 cm accuracy so that the results from imaging and planning can be used effectively during the surgical procedure.
Once the planning process is completed, the patient is transferred to the operating room and a hole is drilled into the patient's skull (0.5″ to 1.0″). At this point, most surgery centers will perform a real time physiological localization of the target area to augment and verify the previously obtained stereotactic data by observing the patients response to stimulation through the DBS electrodes or by recording and displaying (visual or audible) the action potentials of individual neurons along the path way to the target zone using microelectrodes. The additional step is considered necessary because the shape of the brain and the position of anatomical structures can change during neuro-surgical procedures. Such changes can be due to differences between the patient's position in acquisition and during surgery, reduction in volume due to tissue resection or cyst drainage, tissue displacement by the instruments used, changes in blood and extra cellular fluid volumes, or loss of cerebrospinal fluid when the skull is opened. The amount of brain shift can in a severe case be a centimeter or more and is in most cases between 1 and 2 mm.
In addition to the brain shift phenomenon, some subsection of specific nuclei cannot yet be identified by anatomic means, again requiring a physiological determination of the target area. Given these “uncertainties,” several target runs may be required before the desired results are achieved. Throughout the procedure, responses from the patient are necessary to determine if the target area has been reached and if there are any unwanted site effects. Once the target area has been correctly identified, the microelectrode is removed and replaced with the DBS electrode. Stimulation voltage levels are determined by observing the patient and the physiological response. Once all parameters have been correctly adjusted, the DBS electrode is anchored in the skull, a pacemaker is implanted subcutaneously in the sub-clavicular region and the lead is tunneled under the scalp up the back of the neck to the top of the head.
One of the major shortcomings with stereotactic DBS is the requirement of sub millimeter accuracy in electrode placement for the electrical stimulation of target areas deep inside the brain. As pointed out, brain shifts of 1 to 2 mm can routinely occur between the acquisition of images for the stereotactic surgery and the surgery itself and is either caused by patient transport (misregistration, image distortion), loss of fluid (blood, CSF) or simple tissue displacement by the instruments used. A long recognized solution to these issues has been to perform real time MRI guided surgery. To this end a variety of MRI systems have been developed. “Open MRI” systems which are typically operated at field strength ranging from 0.12 T (Odin) to 1.0 T (Philips) offer a clear advantage in patient access over the closed bore systems ranging in field strength from 1.0 T to 3.0 T. However, these high field short bore systems outperform the low field systems in Signal-to-Noise Ratio since the SNR depends linearly on field strength. Higher SNR translates directly into resolution and/or imaging speed. Efforts have been undertaken to increase the field strength of these open systems (Philips 1.0 T), however, it is not clear that much higher magnetic fields are desirable or achievable due to considerable mechanical challenges of stabilizing the separated pole faces of these magnets and the fact that these magnets are not easily shielded and have a larger fringe field than comparable “closed bore” systems. Furthermore, significant progress has been made to increase the patient access in high field systems as well. Traditionally, whole body 3 T MRI systems have had a length in access of 2 m. Over the past few years dedicated head scanners (Allegra, Siemens) have been developed and have reduced the system length to 1.25 m, allowing relatively easy access to the patient's head. Similar progress has been made in whole body scanners at 1.5 T. Since the actual magnet is significantly shorter (68 to 80 cm) than the overall system further improvements in patient access can be expected. Image quality, speed and patient access are now at a point where true interventional MRI is feasible. All major OEM's have recognized the need for a fully integrated MRI operating room and have made significant progress towards this goal. Siemens has introduced the “BrainSuite”, a fully integrated MRI suite for neuro-surgery. Philips, Siemens and GE have also introduced XMRI systems, combining 1.5 T or 3 T whole body systems with an X-Ray fluoroscopy with a patient table/carrier linking both systems.
Atrial fibrillation and ventricular tachyarrhythmias occurring in patients with structurally abnormal hearts are of great concern in contemporary cardiology. They represent the most frequently encountered tachycardias, account for the most morbidity and mortality, and, despite much progress, remain therapeutic challenges.
Atrial fibrillation affects a larger population than ventricular tachyarrhythmias, with a prevalence of approximately 0.5% in patients 50-59 years old, increasing to 8.8% in patients in their 80's. Framingham data indicate that the age-adjusted prevalence has increased substantially over the last 30 years, with over 2 million people in the United States affected. Atrial fibrillation usually accompanies disorders such as coronary heart disease, cardiomyopathies, and the postoperative state, but occurs in the absence of any recognized abnormality in 10% of cases. Although it may not carry the inherent lethality of a ventricular tachyarrhythmia, it does have a mortality twice that of control subjects. Symptoms which occur during atrial fibrillation result from the often rapid irregular heart rate and the loss of atrio-ventricular (AV) synchrony. These symptoms, side effects of drugs, and most importantly, thrombo-embolic complications in the brain (leading to approximately 75,000 strokes per year), make atrial fibrillation a formidable challenge.
Two strategies have been used for medically managing patients with atrial fibrillations. The first involves rate control and anticoagulation, and the second involves attempts to restore and maintain sinus rhythm. The optimal approach is uncertain. In the majority of patients, attempts are made to restore sinus rhythm with electrical or pharmacologic cardioversion. Current data suggest anticoagulation is needed for 3 to 4 weeks prior to and 2 to 4 weeks following cardioversion to prevent embolization associated with the cardioversion. Chronic antiarrhythmic therapy may be indicated once sinus rhythm is restored. Overall, pharmacologic, therapy is successful in maintaining sinus rhythm in 30 to 50% of patients over one to two years of follow-up. A major disadvantage of antiarrhythmic therapy is the induction of sustained, and sometimes lethal, arrhythmias (proarrhythmia) in up to 10% of patients.
If sinus rhythm cannot be maintained, several approaches are used to control the ventricular response to atrial fibrillation. Pharmacologic agents which slow conduction through the AV node are first tried. When pharmacologic approaches to rate control fail, or result in significant side effects, ablation of the AV node, and placement of a permanent pacemaker may be considered. The substantial incidence of thromboembolic strokes makes chronic anticoagulation important, but bleeding complications are not unusual, and anticoagulation cannot be used in all patients.
In addition to medical management approaches, surgical therapy of atrial fibrillation has also been performed. The surgical-maze procedure, developed by Cox, is an approach for suppressing atrial fibrillation while maintaining atrial functions. This procedure involves creating multiple linear incisions in the left and night atria. These surgical incisions create lines that block conduction and compartmentalize the atrium into distinct segments that remain in communication with the sinus node. By reducing the mass of atrial tissue in each segment, the mass of atrial tissue is insufficient to sustain the multiple reentrant rotors, which are the basis for atrial fibrillation. Surgical approaches to the treatment of atrial fibrillation result in an efficacy of >95% and a low incidence of complications. However, despite these encouraging results, this procedure has not gained widespread acceptance because of the long duration of recovery and risks associated with cardiac surgery.
Invasive studies of the electrical activities of the heart (electrophysiologic studies) have also been used in the diagnosis and therapy of arrhythmias. Focal atrial tachycardias, AV-nodal reentrant tachycardias, accessory pathways, atrial flutter, and idiopathic ventricular tachycardia can be cured by selective destruction of critical electrical pathways with radiofrequency (RF) catheter ablation. Electrophysiologists have attempted to replicate the maze procedure using RF catheter ablation. The procedure is arduous, requiring general anesthesia and procedure durations often greater than 12 hours, with exposure to ionizing x-ray irradiation for over 2 hours. Some patients have sustained cerebrovascular accidents. One of the main limitations of the procedure is the difficulty associated with creating and confirming the presence of continuous linear lesions in the atrium. If the linear lesions have gaps, then activation can pass through the gap and complete a reentrant circuit, thereby sustaining atrial fibrillation or flutter. This difficulty contributes significantly to the long procedure durations discussed above.
Creating and confirming continuous linear lesions and morbidity could be facilitated by improved minimally-invasive techniques for imaging lesions created in the atria. Such an imaging technique may allow the procedure to be based purely on anatomic findings.
The major technology for guiding placement of a catheter is x-ray fluoroscopy. For electrophysiologic studies and ablation, frame rates of 7-15 per second are generally used which allows an operator to see x-ray-derived shadows of the catheters inside the body. Since x-rays traverse the body from one side to the other, all of the structures that are traversed by the x-ray beam contribute to the image. The image, therefore is a superposition of shadows from the entire thickness of the body. Using one projection, therefore, it is only possible to know the position of the catheter perpendicular to the direction of the beam. In order to gain information about the position of the catheter parallel to the beam, it is necessary to use a second beam that is offset at some angle from the original beam, or to move the original beam to another angular position. The intracardiac electro-gram may be used to guide the catheters to the proper cardiac tissue.
Intracardiac ultrasound has been used to overcome deficiencies in identifying soft tissue structures. With ultrasound it is possible to determine exactly where the walls of the heart are with respect to a catheter and the ultrasound probe, but the ultrasound probe is mobile, so there can be doubt where the absolute position of the probe is with respect to the heart.
Neither x-ray fluoroscopy nor intracardiac ultrasound have the ability to accurately and reproducibly identify areas of the heart that have been ablated.
A system known as “non-fluoroscopic electro-anatomic mapping” (U.S. Pat. No. 5,391,199 to Ben-Haim), was developed to allow more accurate positioning of catheters within the heart. That system uses weak magnetic fields and a calibrated magnetic field detector to track the location of a catheter in 3D-space. The system can mark the position of a catheter, but the system relies on having the heart not moving with respect to a marker on the body. The system does not obviate the need for initial placement using x-ray fluoroscopy, and cannot directly image ablated tissue.
Embodiments of fixed, steerable, cooled and Multi Electrode Array probes are described that may incorporate multiple functions, such as the recording of MRI imaging signals, bio potentials (electrophysiological, neurological) and cooling. The probes can significantly reduce heating-induced injury in materials surrounding them and can be easily visualized under MRI or X-ray. Disclosed embodiments are illustrative and not meant to be limiting. Drawings illustrate exemplary embodiments and design principles; absolute or relative dimensions are not to be inferred therefrom as necessarily pertaining to a particular embodiment.
With continued reference to
As described above, a plurality of center conductors may be provided. A center conductor may include a conductive core. A center conductor may include an insulator disposed at least partially about the core along at least a portion of the core. The insulator may be disposed about the core to prevent contact between various cores. The insulator may be disposed along the entire length of the core or along one or portions thereof. In an embodiment, an insulator may be disposed about substantially the entire length of a core except for a distal portion for coupling to an electrode. Insulator may be selectively disposed about core, such as discontinuously or on only a selected aspect of a core, such as an aspect that faces another core. Thus, insulator may be disposed about one or more cores so that one or more center conductors may be touching but cores are not in contact.
The insulator can facilitate positioning a center conductors in close proximity to another center conductor. For example, two center conductors may touch but not have the respective cores be in contact. Such close arrangement of center conductors can permit electrical coupling between the center conductors of high-frequency energy, such as magnetic resonance energy, while preventing coupling of low-frequency energy between the center conductors. Coupling the center conductors for high-frequency energy facilitates receiving magnetic resonance signals with the center conductors because the center conductors so coupled can act as a single electrical entity with respect to the high-frequency energy. Thus, the electrical length of the distal portion 7 of the probe 100 can be preserved, because magnetic resonance energy can be conducted straight through the plurality of center conductors, without allowing the magnetic resonance energy to pass separately through various conductors, thereby creating interference, or causing the high-frequency energy to move through a longer path, thereby unbalancing a magnetic resonance antenna. In contrast, a thin insulating layer can be sufficient to prevent coupling between conductors of the low-frequency signals that may be conducted along selected center conductors. For example, low-frequency coupling may not be desirable when the probe 100 is being operated to measure an electrical potential between two electrodes contacting various tissue regions. If the center conductors were permitted to couple this low-frequency energy, then the potential measurement could be distorted, lost in excessive noise, or attenuated entirely. Similarly, ablation energy delivered along the probe 100 could be shorted between center conductors if the center conductors were permitted to couple low frequency energy.
Thus, the wire insulation is preferably sufficiently thin so that the center conductors are electrically coupled through the insulator at high frequency (e.g., above 10 MHz) but are isolated at frequencies below 0.5 MHz.
Accordingly, insulator properties may be selected to facilitate coupling of high-frequency energy between center conductors, while lessening or inhibiting coupling of low-frequency energy. Properties include the material or materials from which the insulator is made, the thickness of the insulator, the number of layers of insulator, the strength of the magnetic field in which the probe 100 may be immersed, among others.
Because the insulator can prevent coupling of low-frequency energy between the center conductors, the center conductors can be brought into very close proximity to one another, also termed “tightly coupled” to one another. The center conductors may be tightly coupled, for example, by twisted around one another. Twisting or otherwise tight-coupling the center conductors facilitates keeping the center conductors in close proximity in the distal portion 7 of the probe 100, where there may be no, e.g., first dielectric layer to keep the center conductors closely apposed. In addition, because reactive elements need not be interposed between the center conductors to decouple low-frequency energy, manufacture of the probe is simplified. Furthermore, the absence of reactive elements can permit the achievement of small probe diameters. For example, a probe having an outer of diameter of about 15 French or less, suitable for, among other uses, cardiac catheterization, observation, and/or ablation, can be readily constructed using systems and methods disclosed herein. Moreover, deep brain stimulation with a magnetic resonance probe is facilitated, because the diameter can be reduced to, for example, 4 French or less, 3 French or less, 2 French or less, 1.3 French or less, 1 French or less, 0.5 French or less, or even 0.1 French or less. The outer diameter can be affected by the thickness of the center conductor core, thickness of insulator, and thicknesses of other layers that may be included. In an embodiment, wire may be used having a thickness of 56 AWG to 16 AWG as well as thinner and/or thicker wire.
A preferred insulator thickness may be determined as follows. The inductance L and capacitance C between a twisted pair of wires per unit length is given by the equations:
where ε0=8.854 pF/m, d is the bare wire diameter in meters, D is the insulated wire diameter in meters, and εr is the relative dielectric constant of the insulating material. In one illustrative embodiment, a 33 AWG magnet wire was used, the wire having a nominal bare wire diameter of 0.0071″ (0.00018034 m) and an insulated diameter of 0.0078″ (0.00019812 m) and an approximate dielectric constant of εr=2. Thus, the insulator thickness was about 17.78 microns, or about 8.89 microns on a side. In this exemplary case the estimated capacitance per unit length is 89 pF/m. This corresponds to a capacitive impedance Zc=1/(2*π*f) of about 28 Ω/m at 63.86 MHz and giving a good coupling at the high frequency range. Because the impedance scales inversely with frequency, the low frequency impedance at 100 kHz is estimated to be 14 kΩ/m. An impedance of 10 kΩ/m or greater is sufficient in most applications to provide sufficient decoupling. The high frequency impedance is preferably kept below 100 Ω/m.
The impedance can also be controlled by the choice of dielectric material. Typical materials include polyurethane resins, polyvinyl acetal resins, polyurethane resins with a polyimide (nylon) overcoat, THEIC modified polyester, THEIC modified polyester with a polyamideimide (AI) overcoat, THEIC modified polyester, oxide-based shield coat and a polyamideimide (AI) overcoat, aromatic polyimide resin, bondable thermoplastic phenoxy overcoat, glass fiber, All Wood Insulating Crepe Paper, Thermally Upgraded Electrical Grade Crepe Kraft Paper, High Temperature Aramid Insulating Paper, and combinations of these. The length of the proximal portion can be modified by selecting dielectric materials for the first dielectric layer and/or second dielectric layers. For example, a material with a high dielectric constant can be incorporated in one or more dielectric layers, thereby decreasing the electrical length of the proximal portion and facilitating use of a probe in a relatively shallow anatomic location. Examples of materials with appropriate dielectric constants include ceramics.
An insulator disposed at least partially about a center conductor core may have a thickness in a range up to about 2,000 microns, preferably up to about 500 microns, more preferably up to about 200 microns, still more preferably up to about 100 microns, yet more preferably in a range between about 1 micron and about 100 microns. An insulator may have a thickness in the range of about 5 microns to about 80 microns. An insulator may a thickness in the range of about 8 microns to about 25 microns. An insulator may a thickness in the range of about 10 microns to about 20 microns.
A core may have an insulator disposed about it by dipping the core in insulator. A core may have an insulator disposed about it by extruding an insulator over the core. A core may have an insulator disposed about it by sliding the core into an insulator or sliding an insulator over a core. A core may have an insulator disposed about it by spraying.
A core may be formed of wire. The wire is preferably thin, to promote small probe size, and may in one embodiment be thin insulated copper wires (33 AWG), at times silver coated. In preferred embodiments, the center conductors are formed of magnetic-resonance compatible material. Preferably, the materials are highly conducting, such as silver clad copper. The outer conductive layer may also be formed of wire, such as braided wire. Other preferred materials include a super elastic material, copper, gold, silver, platinum, iridium, MP35N, tantalum, titanium, Nitinol, L605, gold-platinum-iridium, gold-copper-iridium, and gold-platinum.
As mentioned previously, the plurality of center conductors 2 in the distal portion 7 of the probe 100 may form a first pole of a dipole (loopless) magnetic resonance antenna, while the outer conductive layer 12 in the proximal portion 8 of the probe 100 can form the second pole. As discussed above, the length of the distal portion, or first pole, is preferably approximately the “quarter-wave” length, typically about 3 cm to about 15 cm. The proximal portion or second pole can be of the same length, so that the dipole antenna is balanced. A balanced dipole antenna can provide slightly improved signal quality compared to an unbalanced dipole antenna. However, a proximal portion of approximately even 15 cm may be impractical, because a user might want to introduce a magnetic resonance probe into body structures deeper than 15 cm. In practice, it has been found, fortuitously, that lengthening the proximal portion or second pole, while unbalancing the antenna and slightly degrading image quality, permits visualization of a substantial length of the antenna, which facilitates tracking and localization of the antenna. A significant complication of unbalancing the antenna, namely heating effects during the transmission mode, can be avoided by decoupling the antenna with, for example, a PIN diode, as described below.
The circuits shown in
The MRI system typically alternates between a transmit and receive state during the acquisition of an image. During the transmit phase relatively large amounts of RF energy at the operating frequency of the system, such as about 63.86 MHz, are transmitted into the body. This energy could potentially harm the sensitive receiver electronics and more importantly, the patient, if the imaging antenna, in this case the probe, would be allowed to pick up this RF energy. The antenna function of the probe therefore is preferably turned off so that the probe becomes incapable of receiving RF energy at the MRI system operating frequency. During the receive phase, in contrast, the body emits the RF energy absorbed during the transmit phase at the same frequency, i.e., 63.86 MHz. A significant amount of the transmitted energy is typically lost due to inefficiencies of the transmitter or has been converted into heat by the body. The RF signal emitted by the body containing the image information is typically therefore many orders of magnitude smaller than the original signal send out by the transmitter. In order to receive this small signal, the antenna function of the probe is preferably turned on so that the probe becomes a highly efficient receiver for RF signals at the MRI systems operating frequency. The alternating state of the probe from being a poor RF antenna (receiver) during the transmit phase to being a good RF antenna (receiver) during the receive phase is called T/R (Transmit/Receive) switching and may be facilitated via a control signal send by the MRI system on the center conductor of connector 15 in
During the transmit phase, the positive voltage on the center conductor of connector 15 with respect to the system ground 14 may cause the PIN diode 21 to be conductive and can therefore short the top end of capacitors 23 to ground. The capacitors 23 in combination with the proximal length of the probe form a transmission line; thus, the impedance at the top of the capacitor 23 can be transformed via this transmission line to an impedance ZJ at the junction J connecting the poles of the electric dipole antenna in
With continued reference to
The T/R switching voltages are preferably not passed onto the probe since the switching voltage, which can have a frequency around 1 kHz, may cause unwanted stimulation of the organ or tissue under examination. To combat this, capacitors 23, providing a high-pass filter function, can block propagation of the T/R switching voltage into the probe.
With further reference to
Electrophysiological (EP) signals may be measured independently of the Transmit/Receive state of the MRI system because these signals are typically in a frequency range far below the MRI signal frequency and are separate from the MRI signal via a filter, such as the signal split and low-pass filter depicted in
As depicted in
With further reference to
Probes disclosed herein can facilitate three dimensional electro-anatomical imaging. As depicted in
An electrode can be disposed on an arm. An electrode may be affixed to an arm. An electrode may be glued or bonded to an arm. An arm may include more than one electrode. A basket probe with, e.g., 8 expandable ribs and each carrying, e.g., 8 electrodes is depicted.
Steerable probes may be modified for MR compatibility by using non-magnetic materials. Steerable probes may be modified for MR compatibility by using materials which create few or no susceptibility artifacts. Appropriate materials include, e.g., polymers/plastics, metals—Nitinol, copper, silver or gold, gold platinum alloy, MP35N alloy, etc. An exemplary design of the probes is shown in
Alternatively, as shown in
Additional teachings regarding construction of magnetic resonance probes, selection of materials, preferable dimensions of components, and electrical properties of probes are provided, e.g., in U.S. Pat. Nos. 5,928,145, 6,263,229, 6,549,800, and in U.S. patent application Publication Ser. Nos. US 2002/0,045,816 A1, US 2002/0,161,421 A1, US 2003/0,028,095 A1, and US 2003/0,050,557 A1, all of which patents and patent application publications are hereby incorporated herein in their entireties by this reference.
While the disclosed systems and methods have been described in connection with embodiments shown and described in detail, various modifications and improvements thereon will become readily apparent to those skilled in the art. Accordingly, the spirit and scope of the present disclosure is limited only by the following claims.
Karmarkar, Parag, Viohl, Ingmar
Patent | Priority | Assignee | Title |
10092367, | Mar 18 2014 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
10188462, | Jun 27 2012 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
10327830, | Apr 01 2015 | MONTERIS MEDICAL CORPORATION | Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor |
10342632, | Mar 18 2014 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
10426374, | Aug 30 2016 | The Regents of the University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
10426375, | Aug 30 2016 | The Regents of the University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
10548678, | Jun 27 2012 | MONTERIS MEDICAL CORPORATION | Method and device for effecting thermal therapy of a tissue |
10610317, | Jun 27 2012 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
10646201, | Nov 18 2014 | C. R. Bard, Inc. | Ultrasound imaging system having automatic image presentation |
10675113, | Mar 18 2014 | MONTERIS MEDICAL CORPORATION | Automated therapy of a three-dimensional tissue region |
10905396, | Nov 18 2014 | C. R. Bard, Inc. | Ultrasound imaging system having automatic image presentation |
11298041, | Aug 30 2016 | The Regents of the University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
11298043, | Aug 30 2016 | The Regents of the University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
11497576, | Jul 17 2017 | Voyager Therapeutics, Inc.; The Regents of the University of California | Trajectory array guide system |
11672583, | Apr 01 2015 | MONTERIS MEDICAL CORPORATION | Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor |
11696746, | Nov 18 2014 | C.R. Bard, Inc. | Ultrasound imaging system having automatic image presentation |
8509876, | Aug 09 2004 | Johns Hopkins University, The | Implantable MRI compatible stimulation leads and antennas and related systems and methods |
8979871, | Jun 27 2012 | MONTERIS MEDICAL US, INC ; MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
9211157, | Jun 27 2012 | MONTERIS MEDICAL CORPORATION | Probe driver |
9259556, | Jan 03 2008 | The United States of America, as represented by the Secretary, Department of Health and Human Services | MRI guidewire |
9271794, | Jun 27 2012 | MONTERIS MEDICAL CORPORATION | Monitoring and noise masking of thermal therapy |
9333038, | Jun 15 2000 | MONTERIS MEDICAL CORPORATION | Hyperthermia treatment and probe therefore |
9387042, | Jun 15 2000 | MONTERIS MEDICAL CORPORATION | Hyperthermia treatment and probe therefor |
9433383, | Mar 18 2014 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
9486170, | Mar 18 2014 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
9492121, | Mar 18 2014 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
9504484, | Mar 18 2014 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
9510909, | Jun 27 2012 | MONTERIS MEDICAL CORPORATION | Image-guide therapy of a tissue |
9700342, | Mar 18 2014 | MONTERIS MEDICAL CORPORATION | Image-guided therapy of a tissue |
Patent | Priority | Assignee | Title |
3871382, | |||
3968802, | Jan 24 1975 | Medtronic, Inc. | Cautery protection circuit for a heart pacemaker |
4295467, | May 24 1979 | Styling Technology Corporation | Electrolysis apparatus with retractable probe |
4431005, | May 07 1981 | MBO LABORATORIES, INC , A CORP OF MA | Method of and apparatus for determining very accurately the position of a device inside biological tissue |
4445501, | May 07 1981 | MBO LABORATORIES, INC , A CORP OF MA | Circuits for determining very accurately the position of a device inside biological tissue |
4572198, | Jun 18 1984 | Varian, Inc | Catheter for use with NMR imaging systems |
4633181, | Aug 11 1983 | Regents of the University of California, The | Apparatus and method for increasing the sensitivity of a nuclear magnetic resonance probe |
4643186, | Oct 30 1985 | RCA Corporation | Percutaneous transluminal microwave catheter angioplasty |
4654880, | Dec 09 1983 | Cochlear Corporation | Signal transmission system |
4672972, | Aug 13 1984 | Solid state NMR probe | |
4682125, | Feb 10 1986 | REGENTS OF THE UNIVERSITY OF CALIFORNIA THE | RF coil coupling for MRI with tuned RF rejection circuit using coax shield choke |
4689621, | Mar 31 1986 | The United States of America as represented by the Administrator of the | Temperature responsive transmitter |
4754752, | Jul 28 1986 | TRIMEDYNE, INC | Vascular catheter |
4757820, | Mar 15 1985 | Kabushiki Kaisha Toshiba | Ultrasound therapy system |
4766381, | Aug 12 1987 | Vanderbilt University | Driven inversion spin echo magnetic resonance imaging |
4799499, | Aug 17 1985 | Implantable electrode with active fixation means | |
4813429, | May 12 1986 | Biodan Medical Systems Ltd. | Catheter and probe |
4823812, | May 12 1986 | Biodan Medical Systems Ltd. | Applicator for insertion into a body opening for medical purposes |
4832023, | Jun 03 1987 | MCM LABORATORIES, INC , A CORP OF CA | Method and apparatus for reducing blockage in body channels |
4858623, | Jul 13 1987 | Intermedics, Inc. | Active fixation mechanism for lead assembly of an implantable cardiac stimulator |
4859950, | May 26 1987 | GENERAL ELECTRIC MEDICAL SYSTEMS ISRAEL LTD , AN ISRAEL CORPORATION AFFILIATED WITH GENERAL ELECTRIC COMPANY | Balun circuit for radio frequency coils in magnetic resonance systems |
4932411, | Aug 09 1984 | Siemens Aktiengesellschaft | Intervivo coil for a nuclear magnetic resonance tomographic apparatus |
4951672, | Jul 02 1985 | General Electric Company | Controlled impedance monitoring lead wires |
4960106, | Apr 28 1987 | Olympus Optical Co., Ltd. | Endoscope apparatus |
4989608, | Jul 02 1987 | RATNER, ADAM V | Device construction and method facilitating magnetic resonance imaging of foreign objects in a body |
5019075, | Oct 24 1984 | The Beth Israel Hospital | Method and apparatus for angioplasty |
5095911, | May 18 1990 | Boston Scientific Scimed, Inc | Guidewire with imaging capability |
5099208, | Oct 05 1989 | Vanderbilt University | Method for magnetic resonance imaging and related apparatus |
5125896, | Oct 10 1990 | Boston Scientific Scimed, Inc | Steerable electrode catheter |
5167233, | Jan 07 1991 | Volcano Corporation | Dilating and imaging apparatus |
5170789, | Jun 17 1987 | Insertable NMR coil probe | |
5178618, | Jan 16 1991 | Brigham and Womens Hospital | Method and device for recanalization of a body passageway |
5190046, | May 01 1992 | Shturman Cardiology Systems, Inc.; SHTURMAN CARDIOLOGY SYSTEMS, INC A CORP OF MINNESOTA | Ultrasound imaging balloon catheter |
5209233, | Aug 09 1985 | Picker International, Inc.; PICKER INTERNATIONAL, INC , A CORP OF NY | Temperature sensing and control system for cardiac monitoring electrodes |
5211165, | Sep 03 1991 | General Electric Company | Tracking system to follow the position and orientation of a device with radiofrequency field gradients |
5217010, | May 28 1991 | The Johns Hopkins University | ECG amplifier and cardiac pacemaker for use during magnetic resonance imaging |
5246438, | Nov 25 1988 | INNOVATIVE CARDIAC SOLUTIONS, INC | Method of radiofrequency ablation |
5271400, | Apr 01 1992 | General Electric Company | Tracking system to monitor the position and orientation of a device using magnetic resonance detection of a sample contained within the device |
5300108, | Jan 05 1993 | Pacesetter, Inc | Active fixation lead with a dual-pitch, free spinning compound screw |
5307808, | Apr 01 1992 | General Electric Company | Tracking system and pulse sequences to monitor the position of a device using magnetic resonance |
5307814, | Sep 17 1991 | MEDRAD, INC | Externally moveable intracavity probe for MRI imaging and spectroscopy |
5315025, | Oct 19 1984 | Zeneca Limited | Fungicides |
5318025, | Apr 01 1992 | General Electric Company | Tracking system to monitor the position and orientation of a device using multiplexed magnetic resonance detection |
5323776, | Oct 15 1992 | Picker International, Inc. | MRI compatible pulse oximetry system |
5323778, | Nov 05 1991 | BRIGHAM AND WOMEN S HOSPITAL | Method and apparatus for magnetic resonance imaging and heating tissues |
5333095, | May 03 1993 | GREATBATCH, LTD NEW YORK CORPORATION | Feedthrough filter capacitor assembly for human implant |
5334193, | Nov 13 1992 | American Cardiac Ablation Co., Inc.; AMERICAN CARDIAC ABLATION, CO , INC | Fluid cooled ablation catheter |
5348010, | Feb 24 1989 | MEDRAD, INC | Intracavity probe and interface device for MRI imaging and spectroscopy |
5352979, | Aug 07 1992 | Magnetic resonance imaging with contrast enhanced phase angle reconstruction | |
5355087, | Feb 27 1989 | MEDRAD, INC | Intracavity probe and interface device for MRI imaging and spectroscopy |
5358515, | Aug 16 1989 | Deutsches Krebsforschungzentrum Stiftung des Offentlichen Rechts | Microwave hyperthermia applicator |
5363845, | Aug 13 1993 | Medical Advances, Inc. | Breast coil for magnetic resonance imaging |
5365928, | Nov 25 1992 | MEDRAD, INC | Endorectal probe with planar moveable MRI coil |
5370644, | Nov 25 1988 | INNOVATIVE CARDIAC SOLUTIONS, INC | Radiofrequency ablation catheter |
5398683, | May 24 1991 | EP Technologies, Inc. | Combination monophasic action potential/ablation catheter and high-performance filter system |
5400787, | Nov 24 1993 | MAGNA-LAB, INC | Inflatable magnetic resonance imaging sensing coil assembly positioning and retaining device and method for using the same |
5413104, | Nov 10 1992 | DRAGER MEDICAL ELECTRONICS B V | Invasive MRI transducers |
5419325, | Jun 23 1994 | General Electric Company | Magnetic resonance (MR) angiography using a faraday catheter |
5433717, | Mar 23 1993 | Regents of the University of California, The | Magnetic resonance imaging assisted cryosurgery |
5437277, | Nov 18 1991 | General Electric Company | Inductively coupled RF tracking system for use in invasive imaging of a living body |
5443066, | Jan 29 1993 | General Electric Company | Invasive system employing a radiofrequency tracking system |
5443489, | Jul 20 1993 | Biosense, Inc. | Apparatus and method for ablation |
5447156, | Apr 04 1994 | General Electric Company | Magnetic resonance (MR) active invasive devices for the generation of selective MR angiograms |
5451232, | Oct 07 1991 | Medrad, Inc.; The Trustees of the University of Pennsylvania | Probe for MRI imaging and spectroscopy particularly in the cervical region |
5462055, | Aug 23 1994 | Northrop Grumman Corporation | MRI/hyperthermia dual function antenna system |
5476095, | Feb 24 1989 | Medrad, Inc.; University of Pennsylvania | Intracavity probe and interface device for MRI imaging and spectroscopy |
5498261, | Dec 20 1991 | Advanced Cardiovascular Systems, Inc. | Thermal angioplasty system |
5507743, | Nov 08 1993 | AngioDynamics, Inc | Coiled RF electrode treatment apparatus |
5512825, | Nov 25 1994 | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, THE | Method of minimizing dead-periods in magnetic resonance imaging pulse sequences and associated apparatus |
5514173, | Jan 05 1993 | Pacesetter, Inc | Active fixation lead with a dual-pitch, free spinning compound screw |
5540679, | Oct 05 1992 | Boston Scientific Scimed, Inc | Device and method for heating tissue in a patient's body |
5540959, | Feb 21 1995 | BIOPHAN TECHNOLOGIES, INC | Process for preparing a coated substrate |
5545201, | Mar 29 1995 | Pacesetter, Inc.; Pacesetter, Inc | Bipolar active fixation lead for sensing and pacing the heart |
5558093, | May 18 1990 | Boston Scientific Scimed, Inc | Guidewire with imaging capability |
5578008, | Apr 22 1992 | Japan Crescent, Inc. | Heated balloon catheter |
5588432, | Mar 21 1988 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials, and ablating tissue |
5590657, | Nov 06 1995 | MICHIGAN, UNIVERSITY OF, THE REGENTS | Phased array ultrasound system and method for cardiac ablation |
5620476, | Nov 13 1995 | Pacesetter, Inc.; Pacesetter, Inc | Implantable medical device having shielded and filtered feedthrough assembly and methods for making such assembly |
5623241, | Sep 11 1992 | Magna-Lab, Inc. | Permanent magnetic structure |
5629622, | Jul 11 1995 | Koninklijke Philips Electronics N V | Magnetic field sense system for the protection of connected electronic devices |
5647361, | Dec 18 1992 | Fonar Corporation | Magnetic resonance imaging method and apparatus for guiding invasive therapy |
5662108, | Sep 23 1992 | ST JUDE MEDICAL, ATRIAL FIBRILLATION DIVISION, INC | Electrophysiology mapping system |
5682897, | May 18 1990 | Boston Scientific Scimed, Inc | Guidewire with imaging capability |
5685878, | Nov 13 1995 | Boston Scientific Scimed, Inc | Snap fit distal assembly for an ablation catheter |
5697958, | Jun 07 1995 | SULZER INTERMEDICS INC | Electromagnetic noise detector for implantable medical devices |
5699801, | Jun 01 1995 | Johns Hopkins University, The | Method of internal magnetic resonance imaging and spectroscopic analysis and associated apparatus |
5706810, | Mar 23 1993 | The Regents of the University of California | Magnetic resonance imaging assisted cryosurgery |
5715825, | Mar 21 1988 | Boston Scientific Corporation | Acoustic imaging catheter and the like |
5716390, | Aug 09 1996 | Pacesetter, Inc. | Reduced diameter active fixation pacing lead using concentric interleaved coils |
5722998, | Jun 07 1995 | Intermedics, Inc. | Apparatus and method for the control of an implantable medical device |
5741321, | Jan 11 1996 | Medtronic, Inc.; Medtronic, Inc | Active fixation medical electrical lead having improved turning tool |
5751539, | Apr 30 1996 | GREATBATCH, LTD NEW YORK CORPORATION | EMI filter for human implantable heart defibrillators and pacemakers |
5759202, | Apr 28 1997 | Intermedics Inc | Endocardial lead with lateral active fixation |
5769800, | Mar 15 1995 | ZOLL CIRCULATION, INC | Vest design for a cardiopulmonary resuscitation system |
5775338, | Jan 10 1997 | Boston Scientific Scimed, Inc | Heated perfusion balloon for reduction of restenosis |
5779669, | Oct 28 1996 | Boston Scientific Scimed, Inc | Steerable catheter with fixed curve |
5782891, | Jun 16 1994 | Medtronic, Inc | Implantable ceramic enclosure for pacing, neurological, and other medical applications in the human body |
5792055, | Mar 18 1994 | Schneider (USA) Inc. | Guidewire antenna |
5827997, | Sep 30 1994 | Metal filaments for electromagnetic interference shielding | |
5833608, | Oct 06 1993 | Biosense, Inc. | Magnetic determination of position and orientation |
5836992, | Oct 04 1994 | Medtronic, Inc. | Filtered feedthrough assembly for implantable medical device |
5840031, | Jul 01 1993 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials and ablating tissue |
5864234, | Apr 24 1996 | U S PHILIPS CORPORATION | Image synthesizing method for forming a composite image from basic images |
5868674, | Nov 24 1995 | U S PHILIPS CORPORATION | MRI-system and catheter for interventional procedures |
5879347, | Apr 25 1997 | Ethicon, Inc | Apparatus for controlled thermal treatment of tissue |
5891134, | Sep 24 1996 | Ethicon, Inc | System and method for applying thermal energy to tissue |
5896267, | Jul 10 1997 | GREATBATCH, LTD NEW YORK CORPORATION | Substrate mounted filter for feedthrough devices |
5905627, | Sep 10 1997 | GREATBATCH, LTD NEW YORK CORPORATION | Internally grounded feedthrough filter capacitor |
5916162, | Sep 02 1996 | U.S. Philips Corporation | Invasive device for use in a magnetic resonance imaging apparatus |
5928145, | Apr 25 1996 | The Johns Hopkins University | Method of magnetic resonance imaging and spectroscopic analysis and associated apparatus employing a loopless antenna |
5928159, | Mar 03 1995 | Intact Medical Corporation | Apparatus and method for characterization and treatment of tumors |
5938609, | May 18 1990 | Boston Scientific Scimed, Inc | Guidewire with imaging capability |
5938692, | Mar 26 1996 | PROJECT TROJAN INTELLECTUAL PROPERTY ACQUISITION, LLC; AUSLO RESEARCH LLC | Voltage controlled variable tuning antenna |
5959829, | Feb 18 1998 | GREATBATCH, LTD NEW YORK CORPORATION | Chip capacitor electromagnetic interference filter |
5964705, | Aug 22 1997 | Image-Guided Drug Delivery System, Inc. | MR-compatible medical devices |
5973906, | Mar 17 1998 | GREATBATCH, LTD NEW YORK CORPORATION | Chip capacitors and chip capacitor electromagnetic interference filters |
5978204, | Nov 18 1996 | GREATBATCH, LTD NEW YORK CORPORATION | Capacitor with dual element electrode plates |
6004269, | Jul 01 1993 | Boston Scientific Scimed, Inc | Catheters for imaging, sensing electrical potentials, and ablating tissue |
6008980, | Nov 13 1997 | GREATBATCH, LTD NEW YORK CORPORATION | Hermetically sealed EMI feedthrough filter capacitor for human implant and other applications |
6011995, | Dec 29 1997 | The Regents of the University of California | Endovascular device for hyperthermia and angioplasty and method for using the same |
6026316, | May 15 1997 | Regents of the University of Minnesota | Method and apparatus for use with MR imaging |
6027500, | May 05 1998 | MARQUETTE MEDICAL SYSTEMS, INC | Cardiac ablation system |
6031375, | Nov 26 1996 | Johns Hopkins University, The | Method of magnetic resonance analysis employing cylindrical coordinates and an associated apparatus |
6045532, | Feb 20 1998 | Arthrocare Corporation | Systems and methods for electrosurgical treatment of tissue in the brain and spinal cord |
6055457, | Mar 13 1998 | Medtronic, Inc. | Single pass A-V lead with active fixation device |
6066136, | Jun 13 1997 | Sulzer Osypka GmbH | Ablation catheter with a plurality of poles |
6101417, | May 12 1998 | Pacesetter, Inc.; Pacesetter, Inc | Implantable electrical device incorporating a magnetoresistive magnetic field sensor |
6128522, | May 23 1997 | Koninklijke Philips Electronics N V | MRI-guided therapeutic unit and methods |
6129670, | Nov 24 1997 | CMSI HOLDINGS CORP ; IMPAC MEDICAL SYSTEMS, INC | Real time brachytherapy spatial registration and visualization system |
6141594, | Jul 22 1998 | Cardiac Pacemakers, Inc | Single pass lead and system with active and passive fixation elements |
6159560, | Nov 25 1998 | GREATBATCH, LTD NEW YORK CORPORATION | Process for depositing a metal coating on a metallic component of an electrical structure |
6171240, | Dec 05 1996 | Picker International, Inc.; PICKER INTERNATIONAL, INC | MRI RF catheter coil |
6171241, | Jun 12 1997 | NCNEIL-PPC, INC | Method for measuring myocardial motion and the like |
6188219, | Jan 22 1999 | The Johns Hopkins University | Magnetic resonance imaging method and apparatus and method of calibrating the same |
6226545, | Oct 07 1997 | MARCONI MEDICAL SYSTEMS, INC | RF coil structure for intra-cavity use in magnetic resonance imaging |
6236205, | Dec 16 1997 | U.S. Philips Corporation | MR device provided with a medical instrument, and method of determining the position of the medical instrument |
6238390, | May 27 1998 | Irvine Biomedical, Inc.; IRVINE BIOMEDICAL, INC | Ablation catheter system having linear lesion capabilities |
6263229, | Nov 13 1998 | Johns Hopkins University School of Medicine | Miniature magnetic resonance catheter coils and related methods |
6272370, | Aug 07 1998 | STEREOTAXIS, INC | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
6275369, | Nov 13 1997 | GREATBATCH, LTD NEW YORK CORPORATION | EMI filter feedthough terminal assembly having a capture flange to facilitate automated assembly |
6280385, | Oct 13 1997 | AMRIS PATENTE VERWALTUNGS GMBH & CO KG | Stent and MR imaging process for the imaging and the determination of the position of a stent |
6284971, | Nov 25 1998 | Johns Hopkins University | Enhanced safety coaxial cables |
6332089, | Aug 26 1996 | Biosense, Inc. | Medical procedures and apparatus using intrabody probes |
6390996, | Nov 09 1998 | ZOLL CIRCULATION, INC | CPR chest compression monitor |
6408202, | Nov 03 1998 | The Johns Hopkins University School of Medicine | Transesophageal magnetic resonance analysis method and apparatus |
6414835, | Mar 01 2000 | Medtronic, Inc | Capacitive filtered feedthrough array for an implantable medical device |
6424234, | Sep 18 1998 | GREATBATCH, LTD NEW YORK CORPORATION | ELECTROMAGNETIC INTERFERENCE (EMI) FILTER AND PROCESS FOR PROVIDING ELECTROMAGNETIC COMPATIBILITY OF AN ELECTRONIC DEVICE WHILE IN THE PRESENCE OF AN ELECTROMAGNETIC EMITTER OPERATING AT THE SAME FREQUENCY |
6428537, | May 22 1998 | Boston Scientific Scimed, Inc | Electrophysiological treatment methods and apparatus employing high voltage pulse to render tissue temporarily unresponsive |
6456481, | May 31 2001 | GREATBATCH, LTD NEW YORK CORPORATION | Integrated EMI filter-DC blocking capacitor |
6459935, | Jul 13 2000 | AVX Corporation | Integrated filter feed-thru |
6473291, | Mar 16 1999 | Greatbatch Ltd | Low inductance four terminal capacitor lead frame |
6493591, | Jul 19 2000 | Medtronic, Inc | Implantable active fixation lead with guidewire tip |
6529103, | Sep 07 2000 | GREATBATCH, LTD NEW YORK CORPORATION | Internally grounded feedthrough filter capacitor with improved ground plane design for human implant and other applications |
6535766, | Aug 26 2000 | Medtronic, Inc. | Implanted medical device telemetry using integrated microelectromechanical filtering |
6539253, | Aug 26 2000 | Medtronic, Inc. | Implantable medical device incorporating integrated circuit notch filters |
6549800, | Apr 25 1996 | Johns Hopkins University School of Medicine | Methods for in vivo magnetic resonance imaging |
6556009, | Dec 11 2000 | The United States of America as represented by the Department of Health and Human Services; HEALTH AND HUMAN SERVICES, UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF | Accelerated magnetic resonance imaging using a parallel spatial filter |
6566978, | Sep 07 2000 | GREATBATCH, LTD NEW YORK CORPORATION | Feedthrough capacitor filter assemblies with leak detection vents |
6567259, | May 31 2001 | GREATBATCH, LTD NEW YORK CORPORATION | Monolithic ceramic capacitor with barium titinate dielectric curie point optimized for active implantable medical devices operating at 37°C C. |
6567703, | Nov 08 2000 | Medtronic, Inc.; Medtronic, Inc | Implantable medical device incorporating miniaturized circuit module |
6593884, | Aug 02 1998 | Covidien LP | Intrabody navigation system for medical applications |
6606513, | Feb 01 2000 | LANDMARK COMMUNITY BANK | Magnetic resonance imaging transseptal needle antenna |
6628980, | Mar 24 2000 | LANDMARK COMMUNITY BANK | Apparatus, systems, and methods for in vivo magnetic resonance imaging |
6633780, | Jun 07 1999 | Johns Hopkins University | Cardiac shock electrode system and corresponding implantable defibrillator system |
6643903, | Nov 13 1997 | GREATBATCH, LTD NEW YORK CORPORATION | Process for manufacturing an EMI filter feedthrough terminal assembly |
6654628, | Nov 03 2000 | The Johns Hopkins University | Methods to assess vascular endothelial function |
6675033, | Apr 15 1999 | LANDMARK COMMUNITY BANK | Magnetic resonance imaging guidewire probe |
6675779, | Jun 13 2002 | FCA US LLC | Dual float valve for fuel tank vent with liquid carryover filter |
6687550, | Jun 01 2001 | Pacesetter, Inc.; Pacesetter, Inc | Active fixation electrode lead having an electrical coupling mechanism |
6690963, | Jan 24 1995 | Biosense, Inc | System for determining the location and orientation of an invasive medical instrument |
6701176, | Nov 04 1998 | Johns Hopkins University School of Medicine | Magnetic-resonance-guided imaging, electrophysiology, and ablation |
6714809, | Nov 20 2000 | LANDMARK COMMUNITY BANK | Connector and guidewire connectable thereto |
6765780, | Feb 28 2002 | GREATBATCH, LTD NEW YORK CORPORATION | EMI feedthrough filter terminal assembly having surface mounted, internally grounded hybrid capacitor |
6771067, | Apr 03 2001 | The United States of America as represented by the Department of Health and Human Services | Ghost artifact cancellation using phased array processing |
6829509, | Feb 20 2001 | Medtronic, Inc | Electromagnetic interference immune tissue invasive system |
6847837, | Oct 13 1997 | AMRIS PATENTE VERWALTUNGS GMBH & CO KG | MR imaging method and medical device for use in method |
6868288, | Aug 26 2000 | Medtronic, Inc. | Implanted medical device telemetry using integrated thin film bulk acoustic resonator filtering |
6876885, | Jan 31 2001 | Medtronic, Inc.; Medtronic, Inc | Implantable bifurcated gastrointestinal lead with active fixation |
6882248, | Sep 07 2000 | GREATBATCH, LTD NEW YORK CORPORATION | EMI filtered connectors using internally grounded feedthrough capacitors |
6898454, | Apr 25 1996 | LANDMARK COMMUNITY BANK | Systems and methods for evaluating the urethra and the periurethral tissues |
6904307, | May 29 2002 | SURGI-VISION, INC | Magnetic resonance probes |
6925328, | Apr 20 2000 | Medtronic, Inc | MRI-compatible implantable device |
6931286, | Oct 20 2002 | Medtronic, Inc. | Delivery of active fixation implatable lead systems |
6949929, | Jun 24 2003 | Medtronic, Inc | Magnetic resonance imaging interference immune device |
6952613, | Jan 31 2001 | Medtronic, Inc.; Medtronic, Inc | Implantable gastrointestinal lead with active fixation |
6971391, | Dec 18 2002 | BIOPHAN TECHNOLOGIES, INC | Protective assembly |
6985347, | Feb 28 2002 | GREATBATCH, LTD NEW YORK CORPORATION | EMI filter capacitors designed for direct body fluid exposure |
6999818, | May 23 2003 | GREATBATCH, LTD NEW YORK CORPORATION | Inductor capacitor EMI filter for human implant applications |
7012192, | May 10 2004 | GREATBATCH, LTD NEW YORK CORPORATION | Feedthrough terminal assembly with lead wire bonding pad for human implant applications |
7013180, | Jan 29 2002 | METRONIC, INC | Conditioning of coupled electromagnetic signals on a lead |
7038900, | Feb 27 2003 | GREATBATCH, LTD NEW YORK CORPORATION | EMI filter terminal assembly with wire bond pads for human implant applications |
7047074, | Feb 20 2001 | Medtronic, Inc | Electromagnetic interference immune tissue invasive system |
7092766, | Nov 19 2003 | Pacesetter, Inc. | Active fixation lead with multiple density |
7113387, | Feb 28 2002 | GREATBATCH, LTD NEW YORK CORPORATION | EMI filter capacitors designed for direct body fluid exposure |
7133714, | May 29 2002 | LANDMARK COMMUNITY BANK | Magnetic resonance imaging probes |
7155271, | Nov 04 1998 | Johns Hopkins University School of Medicine | System and method for magnetic-resonance-guided electrophysiologic and ablation procedures |
7236816, | Apr 25 1996 | Johns Hopkins University | Biopsy and sampling needle antennas for magnetic resonance imaging-guided biopsies |
7310216, | Feb 27 2003 | Greatbatch Ltd | EMI filter terminal assembly with wire bond pads for human implant applications |
7363090, | Apr 13 2001 | Greatbatch Ltd. | Band stop filter employing a capacitor and an inductor tank circuit to enhance MRI compatibility of active implantable medical devices |
7412276, | Nov 04 1998 | Johns Hopkins University School of Medicine | Brain therapy |
7422568, | Apr 01 2002 | JOHN HOPKINS UNIVERSITY, THE | Device, systems and methods for localized heating of a vessel and/or in combination with MR/NMR imaging of the vessel and surrounding tissue |
20020040185, | |||
20020055678, | |||
20020095197, | |||
20020097050, | |||
20020161421, | |||
20020167315, | |||
20020177771, | |||
20020192688, | |||
20030028094, | |||
20030028095, | |||
20030050557, | |||
20030199755, | |||
20040015079, | |||
20040024434, | |||
20040046557, | |||
20040167392, | |||
20040263173, | |||
20040263174, | |||
20050197677, | |||
20060009819, | |||
20060100506, | |||
20060247684, | |||
20060259093, | |||
20070088416, | |||
20080058635, | |||
EP145430, | |||
EP243573, | |||
EP466424, | |||
EP498996, | |||
EP557127, | |||
EP673621, | |||
EP930509, | |||
EP1021730, | |||
EP9557127, | |||
JP11239572, | |||
JP4071536, | |||
JP60141034, | |||
JP6054823, | |||
JP6070902, | |||
JP61181925, | |||
JP62233905, | |||
JP9094238, | |||
WO10456, | |||
WO25672, | |||
WO2083016, | |||
WO2006031317, | |||
WO8704080, | |||
WO9210213, | |||
WO9423782, | |||
WO9740396, | |||
WO9852461, | |||
WO9919739, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Jun 06 2007 | MRI Interventions, Inc. | (assignment on the face of the patent) | / | |||
Oct 16 2009 | SURGIVISION, INC | Boston Scientific Corporation | SECURITY AGREEMENT | 023379 | /0649 | |
Nov 05 2010 | SURGIVISION, INC | LANDMARK COMMUNITY BANK, AS COLLATERAL AGENT | SECURITY AGREEMENT | 025592 | /0951 | |
May 13 2011 | SURGIVISION, INC | MRI INTERVENTIONS, INC | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 026576 | /0636 | |
Mar 25 2014 | MRI INTERVENTIONS, INC | LANDMARK COMMUNITY BANK | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 032528 | /0536 | |
Mar 25 2014 | MRI INTERVENTIONS, INC | LANDMARK COMMUNITY BANK | CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECTLY LISTED PROPERTY U S PATENT NO 8374667 PREVIOUSLY RECORDED ON REEL 032528 FRAME 0536 ASSIGNOR S HEREBY CONFIRMS THE SECURITY AGREEMENT | 037120 | /0574 | |
Sep 09 2014 | Boston Scientific Corporation | MRI INTERVENTIONS, INC , FORMERLY KNOWN AS SURGIVISION, INC | RELEASE OF SECURITY INTEREST | 033727 | /0668 | |
Mar 02 2022 | LANDMARK COMMUNITY BANK | CLEARPOINT NEURO, INC FORMERLY KNOWN AS MRI INTERVENTIONS, INC AND SURGIVISION, INC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 059177 | /0392 |
Date | Maintenance Fee Events |
Sep 19 2011 | ASPN: Payor Number Assigned. |
Oct 01 2012 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Date | Maintenance Schedule |
Oct 18 2014 | 4 years fee payment window open |
Apr 18 2015 | 6 months grace period start (w surcharge) |
Oct 18 2015 | patent expiry (for year 4) |
Oct 18 2017 | 2 years to revive unintentionally abandoned end. (for year 4) |
Oct 18 2018 | 8 years fee payment window open |
Apr 18 2019 | 6 months grace period start (w surcharge) |
Oct 18 2019 | patent expiry (for year 8) |
Oct 18 2021 | 2 years to revive unintentionally abandoned end. (for year 8) |
Oct 18 2022 | 12 years fee payment window open |
Apr 18 2023 | 6 months grace period start (w surcharge) |
Oct 18 2023 | patent expiry (for year 12) |
Oct 18 2025 | 2 years to revive unintentionally abandoned end. (for year 12) |